Table 3 The complications and outcomes of COVID-19 in middle-aged (40–59 years) patients without comorbidities
Characteristics | All patients N = 119 | Non-severe N = 101 | Severe N = 18 | p Valuea |
|---|---|---|---|---|
ARDS | 26 (21.8) | 8 (7.9) | 18 (100.0) |  < 0.001 |
Sepsis shock | 5 (4.2) | 0 (0) | 5 (27.8) | 0.003 |
Acute liver injury | 16 (13.4) | 8 (7.9) | 8 (44.4) |  < 0.001 |
Acute kidney injury | 3 (2.5) | 1 (0.9) | 2 (11.1) | 0.059 |
Acute cardiac injury | 4 (3.4) | 0 (0) | 4 (22.2) |  < 0.001 |
Time from symptom onset to ARDS (IQR),d | 9 (7,12) | 10 (8,11) | 8 (7,12) | 0.368 |
Time from symptom onset to sepsis shock, median (IQR),d | 12 (9,20) | – | 12 (9,20) | NS |
Time from symptom onset to acute liver injury, median (IQR),d | 12 (9,14) | 11 (8,14) | 13 (11,14) | 0.397 |
Time from symptom onset to acute kidney injury, median (IQR),d | 11 (10,16) | 8 (–) | 16 (14,19) | 0.221 |
Time from symptom onset to acute cardiac injury, median (IQR),d | 15 (13,17) | – | 15 (13,17) | NS |
Time from symptom onset to discharge or death, median (IQR),d | 22 (19,26) | 25 (22,30) | 21 (19,26) | 0.171 |
ICU admission | 11 (9.24) | – | 11 (61.1) | NS |
Mechanical ventilation | 18 (15.1) | – | 18 (100) | NS |
Vasopressor therapy | 5 (4.2) | – | 5 (27.8) | NS |
CRRT | 2 (1.68) | – | 2 (11.1) | NS |
ECMO | 0(0) | – | 0 (0) | NS |
Death | 5 (4.2) | 0 (0) | 5 (27.8) | 0.003 |